The FDA last week revised and reissued the emergency use authorization for COVID-19 convalescent plasma to limit its use to only hospitalized patients early in the course of the disease and those with a medical condition that impairs their ability to make antibodies, The Wall Street Journal reported.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,